Deuruxolitinib is approved to treat severe alopecia areata in adults.
November 2025 in “Journal of Investigative Dermatology” Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.
November 2025 in “Journal of Investigative Dermatology” Chronic refractory alopecia areata has more skin-resident memory T cells, and JAK inhibitors may help reduce them.
November 2025 in “Trends in Immunotherapy” Exosomes from certain cells can improve hair regrowth by changing the immune response.
November 2025 in “The Journal of Immunology” BTNL2 helps protect hair follicles from immune attacks, which could aid in treating alopecia areata.
November 2025 in “The Journal of Immunology” The S1PR 1&4 modulator may effectively treat alopecia areata by reducing hair loss and immune cell activity.
October 2025 in “Science Advances” IFN-γ production by CD4 T cells is crucial for causing alopecia areata.
PCOS involves genetic and immune factors, especially T cells, affecting its development.
Thymoma with alopecia areata may be linked to abnormal immune cells.
July 2025 in “Journal of Investigative Dermatology” Immune system changes may contribute to female pattern hair loss.
July 2025 in “Journal of Investigative Dermatology” Scarring alopecia involves increased immune cells and specific gene changes near damaged hair follicles.
July 2025 in “Journal of Investigative Dermatology” Enhancing Tregs can protect against alopecia areata.
July 2025 in “Journal of Investigative Dermatology” Discoid lupus erythematosus involves immune activation and fibrosis around hair follicles, with shared pathways across humans, dogs, and mice, suggesting potential treatments for both humans and animals.
Alopecia areata involves immune system changes, especially in severe cases, with potential new treatment targets identified.
June 2025 in “Academic Medical Journal” Restoring hair follicle immune privilege may help treat alopecia areata.
May 2025 in “Frontiers in Pharmacology” Targeting gut microbiome and metabolome may help treat autoimmune skin diseases like alopecia areata.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Linoleic acid and magnesium are key in alopecia areata progression, and tofacitinib can help by affecting their pathway.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Linoleic acid and magnesium are key in alopecia areata progression, and tofacitinib can help by affecting their pathway.
May 2025 in “Nonlinear Analysis Real World Applications” Reducing CD8+ T cell growth can stabilize alopecia areata.
CD4 T cells need IFN-γ to cause hair loss in alopecia areata.
March 2025 in “Experimental Dermatology” Overexpression of IKZF1 and Ikaros causes hair loss in mice similar to alopecia areata.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
February 2025 in “International Journal of Molecular Sciences” RIPK1 inhibitors may help prevent alopecia areata by reducing immune cell activity.
February 2025 in “Journal of the European Academy of Dermatology and Venereology” Mogamulizumab can cause hair loss, often linked to a better treatment response.
January 2025 in “Clinical Cosmetic and Investigational Dermatology” Pediatric alopecia areata is more immune-active than adult cases, suggesting age-specific treatments and potential use of JAK inhibitors.
December 2024 in “Journal of Clinical Medicine of Kazakhstan” Vitiligo treatments include JAK inhibitors, UVB phototherapy, and dietary changes, with emotional support being important.
γδTregs may help treat autoimmune diseases like alopecia areata by promoting hair regrowth and reducing immune attacks.
RIPK1 inhibitors might help prevent alopecia areata.
Alopecia universalis from alemtuzumab in multiple sclerosis can be reversed with specific treatments.
July 2024 in “Journal of Investigative Dermatology” CD8+ T cells attack hair follicle stem cells, causing scarring and hair loss in Discoid Lupus.